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Abstract
Background Hemolytic uremic syndrome (HUS) is
characterized by hemolytic anemia, low platelets, and renal
impairment and is mediated by thrombotic microangiopa-
thy (TMA). A common perception is that HUS becomes
dormant in dialysis patients with end-stage renal disease
(ESRD). We analyzed patients in a large dialysis organi-
zation to understand the potential consequences and burden
of HUS.
Methods We identified patients with ESRD ascribed to
HUS and those with ESRD ascribed to another cause
(control patients) who received hemodialysis or peritoneal
dialysis from 01 January 2007 to 31 December 2012.
Outcomes were survival, hospitalization, and longitudinal
laboratory values associated with TMA, including lactate
dehydrogenase, red cell distribution width (RDW), plate-
lets, and hemoglobin.
Results HUS patients (n = 217) were propensity-score
matched 1:5 to control patients (n = 1,085) for age, gen-
der, race, dry weight, insurance, access, comorbidities, and
Charlson comorbidity index. Compared to control patients,
HUS patients had significantly greater risk for hospital-
izations overall (RR = 2.3, p = 0.004) and hospitalization
for hematologic (RR = 5.6, p = 0.001), cardiovascular
(RR = 2.1, p = 0.02), and pancreatic (RR = 7.9,
p = 0.04) causes. HUS patients also had evidence of
ongoing TMA: higher lactate dehydrogenase and RDW,
lower platelets and hemoglobin, and more frequent lactate
dehydrogenase spikes.
Conclusions Dialysis patients with HUS were at signifi-
cantly higher risk than matched control patients for hos-
pitalizations due to cardiovascular, hematologic, and
pancreatic disease, which were associated with ongoing
TMA. Additional studies are needed to determine whether
targeted therapy for HUS reduces hospitalizations.
Keywords Hospitalization  Mortality  Survival
Introduction
Hemolytic uremic syndrome (HUS) is a devastating disease
that is mediated by thrombotic microangiopathy (TMA).
Historically, patients with the disease present with a triad of
clinical signs: thrombocytopenia, hemolytic anemia, and
acute renal failure [1, 2]. It is increasingly recognized that in
addition to renal and hematologic injury, TMA affects
nearly every organ system, including (but not limited to) the
central nervous, cardiovascular, and digestive systems [1].
There are two types of HUS, typical and atypical.
Typical HUS is bacterial in origin, accounts for 90 % of
HUS patients, and generally does not lead to renal failure
in adults [3–6]. Atypical HUS is a genetic disease in which
excessive complement activity leads to TMA, hemolytic
anemia, and acute renal failure [5, 7–9]; it is estimated that
64–67 % of adults with atypical HUS die or reach end-
stage renal disease (ESRD) within 3–5 years of onset [10].
A common perception among clinicians is that HUS
becomes dormant following progression to ESRD. This
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perception may stem, in part, from the inability of patients
to manifest further renal injury in the context of renal
failure. However, emerging evidence indicates that HUS
patients continue to manifest signs and symptoms of TMA
after the onset of ESRD. For example, a 2006 study by
Perkins et al. [11] found that the rate of overt TMA in
dialysis patients with HUS-ascribed ESRD was 11.3 % in
the first year of dialysis and remained at about 4.5 % every
year thereafter; the TMA rate among dialysis patients
without HUS averaged about 0.3 % per year. The
researchers also found that TMA was independently asso-
ciated with an increased risk of death in the first year fol-
lowing a TMA diagnosis.
At present, it remains unknown whether morbidity and
mortality differ between patients with ESRD due to HUS
(which disproportionally consists of atypical versus shiga
toxin-related disease), versus comparable patients with
ESRD due to other etiologies. To clarify burden of disease,
we compared survival, hospitalization, cause-specific hos-
pitalization, and longitudinal laboratory patterns between
patients with ESRD ascribed to HUS versus propensity-
matched control patients with ESRD ascribed to a cause
other than HUS or TMA-related conditions.
Subjects and methods
Patients
We conducted a retrospective study of adult ESRD patients
from a large dialysis organization (LDO) who began
maintenance in-center hemodialysis or peritoneal dialysis
between 01 January 2007 and 31 December 2012. Demo-
graphic and laboratory data were obtained from the LDO’s
clinical data warehouse, which stores the electronic health
records. Hospitalization events and cause-attribution data
[based on International Classification of Diseases, Ninth
Revision (ICD-9) codes] were obtained from Medicare
Claims files, which are made available through the United
States Renal Data System (USRDS) and linked to the
LDO’s electronic health records. Hospitalization analyses
were limited to Medicare patients and were considered
from 01 January 2007 through 31 December 2010 (the last
date of available claims data).
The HUS patients were identified as incident ESRD
patients who began dialysis at the LDO during the study
period with ESRD ascribed to ICD-9 code 283.11 (hemo-
lytic uremic syndrome) (Fig. 1). As there is no ICD-9 code
specific for atypical HUS, both atypical and diarrheal-
associated disease were considered together. Because most
typical cases of HUS occur in children\4 years of age [12]
and because consideration in this study was limited to adult
patients, we presumed the majority of HUS patients had
atypical disease. Eligible control patients were adult
patients who began dialysis at the LDO during the study
period with ESRD ascribed to any etiology other than HUS
or a TMA-related condition (i.e., lupus, scleroderma, an-
tiphospholipid antibody syndrome, malignant hyperten-
sion, eclampsia/preeclampsia/post-partum renal failure,
cholesterol emboli syndrome, Budd–Chiari syndrome,
paroxysmal nocturnal hemoglobinuria, acute interstitial
nephritis, human immunodeficiency virus (HIV)-associated
nephropathy, and heroin nephropathy).
The HUS patients were propensity score matched [13,
14] (1: many; with ratio up to 5) without replacement to
eligible control patients on the basis of age, sex, race/
ethnicity, primary insurance provider, body weight,
dialysis vintage, dialytic modality, and the presence (at
study entry) of hypertension, coronary disease, conges-
tive heart failure, cerebrovascular disease, and peripheral
Fig. 1 Identification of study patients. Identification of patients with
end-stage renal disease (ESRD) ascribed to hemolytic urinary
syndrome (HUS) and matched control patients with ESRD ascribed
to neither HUS nor a thrombotic microangiopathy (TMA)-related
condition. TMA-related conditions are defined as lupus, scleroderma,
antiphospholipid antibody syndrome, malignant hypertension,
eclampsia/preeclampsia/post-partum renal failure, cholesterol emboli
syndrome, Budd–Chiari syndrome, paroxysmal nocturnal hemoglo-
binuria, acute interstitial nephritis, HIV-associated nephropathy, and
heroin nephropathy
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vascular disease. Maximum caliper width was set to
\0.0001.
Measurements
Patients were considered at risk beginning at the time of
dialysis initiation and continuing until death or kidney
transplant, transfer of care away from the LDO, recovery of
renal function, or end-of-study period (31 December 2012;
31 December 2010 for hospitalization analyses).
Baseline characteristics of HUS patients were described
as means, standard deviations (SDs), medians, interquartile
ranges, counts, and proportions as dictated by data type
(continuous or noncontinuous variables). These baseline
characteristics were compared between groups using stan-
dardized differences; standardized differences of absolute
value \10 % are indicative of good balance between
groups.
Statistical analysis
Survival was compared using Kaplan–Meier analysis, log
rank testing, and Cox proportional hazards regression;
regression models were stratified on matched group to
account for the matched design. The proportionality
assumption was assessed by fitting models with 2-way
exposure-by-time cross-product terms. Statistical signifi-
cance of the cross-product term would have been inter-
preted as evidence of non-proportionality; this was not
observed, suggesting that associations were time-invariant.
Rates of hospitalization overall and for each cause-
specific type were compared between HUS patients and
control patients using generalized linear models. Models
were specified with a log link and Poisson distribution and
contained random effects intercepts for patients and fixed
effects terms for exposure status and time. A variance
component matrix was assumed when controlling for
patient correlation (longitudinal observations) over time.
Data on laboratory indices of TMA—platelet count,
lactate dehydrogenase, hemoglobin, and red cell distribu-
tion width (RDW)—were extracted from the LDO’s elec-
tronic health record. These parameters were compared
longitudinally between study groups using linear mixed
models. Missingness was assessed by creating a series of
missing indicator variables (=1 if missing; =0 if present).
For each variable, the association of missingness with
exposure was then assessed using a mixed linear model
with a logit link and binomial distribution, with random
effects intercept for patient and fixed effects terms for
exposure and time (the latter to account for secular patterns
of missingness).
Significant associations between HUS/control status and
missingness would have been interpreted as evidence of
violation of the missing-at-random assumption; this was
not observed for any variables (p[ 0.05 for each).
Longitudinal lactate dehydrogenase spikes were con-
sidered as monthly longitudinal dehydrogenase values that
were 100 U/L or more greater than the patient’s mean
value over the prior 2 months; these were compared
between HUS patients and control patients in an analogous
manner. Analyses of the association between lactate
dehydrogenase spikes and hospitalizations involved a
dichotomous response variable (hospitalization 0/1 in the
response month) and a time-varying dichotomous exposure
variable (lactate dehydrogenase spike 0/1 from prior
month). These associations were therefore analyzed using a
time-updated linear mixed model with a logit link (to
account for the dichotomous nature of the outcome) and
estimates.
Results
Each HUS patient (N = 217) was successfully matched to
5 control patients (N = 1,085) from a pool of 230,668
eligible subject patients (Table 1). Unlike in the source
cohort, HUS patients and control patients in the matched
population were well balanced on covariates: both groups
averaged 48 years and were 57 % female. Race distribu-
tion was similar (75 % white for HUS patients, 74 % for
control patients, and 16 % black patients for both case and
control groups). Medicare was the primary source of
insurance for 35 % of both HUS patients and control
patients. Regarding vascular access, 82 % of HUS patients
versus 81 % of control patients had central venous catheter
access. For HUS patients versus control patients, comor-
bidity patterns were similar for diabetes (11 versus 10 %),
hypertension (47 versus 44 %), coronary artery disease (5
versus 4 %), congestive heart failure (9 versus 8 %),
cerebrovascular disease (3 % for both groups), and
peripheral artery disease (2 % for both groups).
HUS patients and control patients contributed 315 and
1,850 years at risk, respectively. During this time, 39 and
204 deaths were observed corresponding to crude mortality
rates of 12.4 deaths per 100 patient-years for HUS patients
and 11.0 deaths per 100 patient-years for control patients.
Accounting for the matched design, the hazard ratio [95 %
confidence interval (CI)] for death for HUS patients versus
control patients was 1.1 (0.8–1.7; p = 0.5) (Table 2).
For hospitalizations, cumulative at-risk time was 141.2
patient-years for HUS patients and 779.1 patient-years for
matched control patients (Table 3). A total of 176 hospi-
talizations were observed among HUS patients and 719
among control patients: hospitalization rates were 124.7 and
92.3 hospitalizations per 100 patient-years, respectively
(Fig. 2). Incidence rate ratio (IRR) for hospitalization
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among HUS patients versus control patients was 2.3
(1.3–4.1; p = 0.004).
When hospitalizations were considered by primary
cause, it was observed that the rate of hospitalization for
hematological causes [IRR 5.6 (1.9–15.9); p = 0.001],
cardiovascular causes [IRR 2.1 (1.1–4.0); p = 0.02], and
pancreatic causes [IRR 7.9 (1.1–59.8); p = 0.04] were
greater among HUS patients versus matched controls.
Considered longitudinally, HUS patients compared to
control patients had higher mean lactate dehydrogenase
levels (215.9 versus 193.9 U/L, p\ 0.001), lower platelet
levels (240.1 versus 248.1 per lL, p\ 0.001), lower mean
Table 1 Comparison of
baseline characteristics between
hemolytic uremic syndrome




dialysis, SD standard deviation,
Std diff standard difference
Variable HUS patients Source cohort Matched cohort
n = 217 n = 230,668 Std diff n = 1,085 Std diff
Age (years), mean ± SD 48 ± 18 63 ± 15 -1.0 48 ± 16 0.02
Sex, n (%)
Male 93 (43 %) 97,921 (42 %) -0.3 467 (43 %) 0.0
Female 124 (57 %) 132,681 (58 %) 618 (57 %)
Race, n (%)
White 163 (75 %) 116,119 (50 %) 0.5 803 (74 %) 0.1
Black 35 (16 %) 66,812 (29 %) 170 (16 %)
Other 19 (9 %) 47,472 (21 %) 112 (10 %)
Dry weight, mean ± SD 72 ± 19 83 ± 23 -0.5 72 ± 20 -0.0
Primary insurer, n (%)
Medicare 75 (35 %) 134,267 (58 %) 0.5 376 (35 %) 0.1
Medicaid 27 (12 %) 27,062 (12 %) 124 (11 %)
Other 96 (44 %) 52,829 (23 %) 506 (47 %)
Unknown 19 (9 %) 16,510 (7 %) 79 (7 %)
Dual eligibility, n (%) 28 (13 %) 38,049 (17 %) -0.1 139 (13 %) 0.0
Access type, n (%)
Fistula/graft 33 (15 %) 64,580 (28 %) 0.3 180 (17 %) 0.0
Catheter 178 (82 %) 159,418 (69 %) 876 (81 %)
PD 6 (3 %) 6670 (3 %) 29 (3 %)
Diabetes, n (%) 23 (11 %) 90,661 (39 %) -0.7 113 (10 %) 0.0
Hypertension, n (%) 101 (47 %) 118,361 (51 %) -0.1 481 (44 %) 0.0
Coronary artery disease, n (%) 11 (5 %) 22,358 (10 %) -0.2 44 (4 %) 0.0
Congestive heart failure, n (%) 20 (9 %) 41,999 (18 %) -0.3 89 (8 %) 0.0
Cerebrovascular disease, n (%) 7 (3 %) 10,157 (4 %) -0.1 34 (3 %) 0.0
Peripheral arterial disease, n (%) 4 (2 %) 15,866 (7 %) -0.2 17 (2 %) 0.0
Charlson comorbidity index, n (%)
2 104 (48 %) 19,284 (8 %) -1.3 525 (48 %) 0.1
3 37 (17 %) 17,658 (8 %) 179 (17 %)
4 32 (15 %) 36,889 (16 %) 180 (17 %)
5 22 (10 %) 48,370 (21 %) 116 (11 %)
6 15 (7 %) 51,966 (23 %) 57 (5 %)
7 4 (2 %) 33,415 (14 %) 19 (2 %)
8? 3 (1 %) 23,086 (10 %) 9 (1 %)
Table 2 Survival comparison between hemolytic uremic syndrome

















1,085 204 1,850.2 11.0
CI confidence interval, HR hazard ratio, HUS hemolytic uremic
syndrome
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hemoglobin levels (11.1 versus 11.3 g/dL, p\ 0.001), and
higher RDW (15.6 versus 15.3 %, p\ 0.001) (Table 4).
Lactate dehydrogenase spikes were observed in 77 of
2,367 patient months (3.3 %) among HUS patients and 373
of 15,356 patient months (2.4 %) among matched controls:
odds ratio (OR) (95 % CI) = 1.42 (1.05–1.91); p = 0.02.
In the pooled population, lactate dehydrogenase spikes
were associated with a greater risk of subsequent hospi-
talization overall [OR (95 % CI): 1.73 (1.04–2.85);
p = 0.03], hospitalization for hematological causes [OR
(95 % CI): 3.92 (1.32–11.64); p = 0.01] and for infection-
related causes [OR (95 % CI): 2.42 (1.34–4.37);
p = 0.003]; no significant associations were seen for other
types of hospitalization (Fig. 3).
Discussion
Despite the ongoing belief that the presence of HUS
becomes moot once ESRD is reached, this study provides
supporting evidence that TMA continues to manifest after
dialysis is started in patients with HUS-ascribed ESRD.
Among these patients, we found higher hospitalization
rates, particularly for cardiovascular, hematologic, and
pancreatic causes, which are the types of hospitalizations
Table 3 Hospitalization rate comparison between hemolytic uremic syndrome patients and matched control patients









Any cause 176 124.7 719 92.3 2.3 (1.3–4.1) 0.004
Hematologica 14 9.9 25 3.2 5.6 (1.9–15.9) 0.001
Cardiovasculara
Overall 97 68.7 375 48.1 2.1 (1.1–4.0) 0.02
Coronary arterial 4 2.8 21 2.7 1.3 (0.1–12.6) 0.8
Cerebrovascular 6 4.2 30 3.9 0.7 (0.1–4.6) 0.7
Peripheral arterial 0 0 8 1.0 – –
VTE 0 0 4 0.5 – –
Hypertensive crisis 7 5.0 15 1.9 5.6 (0.5–57.9) 0.2
Pulmonary HTN 0 0 0 0 – –
Other CV 80 56.7 297 38.1 2.4 (1.3–4.4) 0.05
Pancreatica 6 4.2 16 2.1 7.9 (1.1–59.8) 0.04
Hepatobiliarya 2 1.4 20 2.6 0.8 (0.0–17.8) 0.9
Intestinala 16 11.3 66 8.5 1.8 (0.6–5.2) 0.3
Infectiousa 35 24.8 187 24.0 1.2 (0.6–2.3) 0.6
Bleedinga 6 4.2 28 3.6 1.0 (0.3–3.3) 1.0
CI confidence interval, CV cardiovascular, HTN hypertension, HUS hemolytic uremic syndrome, IRR incidence rate ratio, pt patient, VTE
venothromboembolism
a Attribution of hospitalization based on primary ICD-9 code
Fig. 2 Hospital admission rates for dialysis patients with end-stage
renal disease ascribed to hemolytic uremic syndrome compared to
dialysis patients with end-stage renal disease ascribed to other causes
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associated with TMA. We also found other evidence of
ongoing TMA in the HUS-ascribed ESRD patients,
including consistently higher lactate dehydrogenase and
RDW levels, as well as lower platelet and hemoglobin
levels, which may reflect a chronic ongoing low-grade
disease process.
Earlier studies have found high TMA recurrence rates
among HUS patients, Shumak et al. [15] found that one
third of their HUS patients relapsed within a year, and
Hayward et al. [16] found a relapse rate of 21.1 % in the
first year following plasma treatment for HUS. More recent
studies have found lower rates of TMA recurrence [5, 11].
A further indication of ongoing TMA was the increased
frequency of lactate dehydrogenase spikes among HUS
patients; this is suggestive of superimposed periods of
disease acceleration. It was notable that hospitalization
rates for TMA-related causes (cardiovascular, hematologic,
and infections) were more common at the time of the
lactate dehydrogenase spike versus other times.
This is the first study to compare HUS and non-HUS-
ascribed ESRD patients in relation to hospitalization. Prior
research has examined the morbidity and mortality of
typical HUS versus atypical HUS patients. One study
found that patients with atypical HUS are hospitalized
more than twice as long during acute episodes compared to
those with typical HUS [5].
The current study found no material difference in sur-
vival between HUS patients and control patients, a finding
supported by an Australian study that found HUS-ascribed
ESRD patients had comparable patient survival while on
dialysis [17].
On balance, there is an important burden of HUS among
patients who have already manifested ESRD vis-a`-vis
hospitalizations, in particular hospitalizations for cardio-
vascular, anemia, and pancreatic causes, which are asso-
ciated with ongoing TMA activity. The current study
provides additional evidence to support the hypothesis that
TMA persists among HUS patients during ESRD as evi-
denced by increased hospitalizations and increased TMA
laboratory findings (lower hemoglobin and platelets, higher
lactate dehydrogenase and RDW levels, and more lactate
dehydrogenase spikes).
One important limitation of this study is the inability to
distinguish between atypical and diarrheal-associated HUS.
Research has shown that atypical HUS patients have poorer
outcomes than those with diarrheal-associated HUS [1, 18,
19]. Because the latter type of patients are generally
healthier than atypical HUS patients, our findings likely
Table 4 Longitudinal
laboratory values for thrombotic
microangiopathy-related
variables between hemolytic
uremic syndrome patients and
control patients
HUS hemolytic uremic
syndrome, Pt patient, RDW red
cell distribution width, SD
standard deviation






Average lactate dehydrogenase (U/L),
mean ± SD
2,655 215.9 ± 114.3 16,665 193.9 ± 65.9 \0.001
Average platelet count (no./lL),
mean ± SD
2,594 240.1 ± 115.931 16,336 248.1 ± 89.0 \0.001
Average hemoglobin (g/dL),
mean ± SD
2,754 11.1 ± 1.4 17,250 11.3 ± 1.3 \0.001
Average RDW (%), mean ± SD 2,590 15.6 ± 2.1 16,338 15.3 ± 1.9 \0.001
Lactate dehydrogenase spikes, n (%) 2,367 77 (3.3 %) 15,356 373 (2.4 %) 0.02
Fig. 3 Temporal associations
between lactate dehydrogenase
(LDH) spikes (LDH[ 100
compared to the mean of the
prior 2 months) and
hospitalization events were
examined in the hemolytic
uremic syndrome patients and
controls. Significant
associations were found for
hospitalization of all-causes
[1.73 (1.04–2.85; p = 0.03)],
hematological causes [3.92
(1.32–11.6; p = 0.01)], and
infection [2.42 (1.34–4.37;
p = 0.003)]
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underestimate the true burden of atypical HUS. Because of
this, studies are needed to test whether directed treatment
of atypical HUS reduces hospitalization rates.
Because this study is retrospective and observational,
there may be some confounding. Propensity score match-
ing was utilized to help minimize confounding.
In conclusion, comparing HUS patients to control
patients—both with ESRD—HUS patients had signifi-
cantly greater rates of hospitalization, particularly for car-
diovascular, hematologic, and pancreatic disease. In
addition, HUS patients exhibited laboratory evidence
consistent with ongoing TMA, which is consistent with the
idea that treatment for HUS may reduce morbidity and
hospitalization rates. Efforts should be directed at identi-
fying patients with ESRD ascribed to HUS to include HUS
treatment to mitigate TMA events.
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